CMO Dr. Andrew Hertler Reacts to the FDA's Recent ODAC Meeting

CMO Dr. Andrew Hertler on the Recent FDA ODAC Meeting

The FDA's Oncologic Drugs Advisory Committee (ODAC) met for the first time in a decade to review the merits of approved cancer drugs and specifically, the status of six indications that were granted accelerated approval. New Century Health CMO Dr. Andrew Hertler recently shared his reactions to ODAC's decisions and his reflections on the clinical oversight and scientific rigor that defines New Century Health's pathway development.
 

 

Previous Article
New Century Health Supports Neighborhood Health Plan of Rhode Island with Comprehensive Oncology Management Services
New Century Health Supports Neighborhood Health Plan of Rhode Island with Comprehensive Oncology Management Services

New Century Health, a national leader in specialty care management, is proud to provide comprehensive oncol...

Next Article
A now-or-never moment for telehealth?
A now-or-never moment for telehealth?

Our CMO Dr. Andrew Hertler speaks with HFMA about the role of telehealth in oncology care today.

×

First Name
Last Name
Company Name
Thank you!
Error - something went wrong!